This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Recently, Sabra Health Care REIT (SBRA - Free Report) announced the selling of nine healthcare facilities leased to Genesis Healthcare (GEN - Free Report) on Jun 29, in a bid to dispose the properties leased to the latter. These healthcare facilities have been sold for $81.4 million.
CXP PSB SBRA PSB.PRV ADI PSB.PRW PSB.PRX PSB.PRY GEN PSB.PRS PSB.PRT PSB.PRU SBRAP
The Ensign Group, Inc. (ENSG - Free Report) boasts a strong inorganic growth story, with more than 234 acquisitions made over 18 years. Its historical growth has been mainly driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming those into market leaders. With each acquisition, the company had sharpened its expertise, both clinically and financially.
LMT PRAH LPNT ENSG GEN
IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that on June 29, 2018, it completed the previously announced sale of nine facilities (seven skilled nursing facilities, one senior housing community and one continuing care retirement community) leased to Genesis Healthcare, Inc. (“Genesis”) for $81.4 million. Under the terms of Sabra’s memoranda of understanding with Genesis, Genesis’s annual rent obligations to Sabra were reduced by $7.
GEN CCP SBRA SBRAP
KENNETT SQUARE, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare, one of the largest post-acute care providers in the United States, today announced that eight of its centers have been recognized as a 2018 recipients of the Bronze – Commitment to Quality Award for their commitment to improving the lives of residents through quality care. The distinction is the first of three progressive award levels through the National Quality Award Program, presented by the American Health Care Association and National Center for Assisted Living (AHCA/NCAL), the leading association for long term and post-acute care.
Oracle reports adjusted earnings of 99 cents a share on sales of $11.25 billion, beating expectations
WFCNP WFC.PRL WFC.PRJ MXWL WFC.PRT WFC.PRR WFC.PRQ FEYE WFC.PRP WFC.PRO WFC.PRN WFC.PRY GEN WFC.PRX WFC.PRW ORCL WFC.PRV DIS ETSY WFC IBM WFC.WS GEC GE XLK DQ OCLCF GNE
gen_Current folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that on June 1, 2018, it completed the previously announced sale of 12 facilities (11 skilled nursing facilities and 1 senior housing community) leased to Genesis Healthcare, Inc. (“Genesis”) located in New Hampshire and Florida for $134.0 million. Under the terms of Sabra’s memoranda of understanding with Genesis, Genesis’s annual rent obligations to Sabra were reduced by $12.
GEN CCP SBRA SBRAP
8h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
9h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to GEN / Genesis Healthcare, Inc. on message board site Silicon Investor.
as of ET